
BURST CME™ Resource Center: Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies
This resource center is supported by an educational grant from Daiichi Sankyo, Inc.
Tenosynovial giant cell tumor (TGCT) is challenging to diagnose and manage, requiring the coordination of clinicians across specialties. In this BURST CME™ activity, 2 experts in TGCT management review the current landscape of diagnosis and treatment, including discussion of the strengths and limitations of established diagnostic approaches and an exploration of the expanding therapeutic arsenal for this disease. Multidisciplinary management of TGCT is also discussed to integrate surgical, systemic, supportive, and rehabilitative care for patients.
CE Activity Curriculum - Physician Credit
Resource Links
CE Activity Curriculum - Physician Credit
Resource Links
Pimicotinib Yields Long-Term Response in Tenosynovial Giant Cell Tumor
Pexidartinib Elicits Sustained Benefit in Tenosynovial Giant Cell Tumor
FDA Approves Vimseltinib in Tenosynovial Giant Cell Tumor
Nurse Tells Patients With TGCT to Speak Out About Pain
FDA Adds REMS Guidelines for Pexidartinib in Tenosynovial Giant Cell Tumor